Predictions
Onxeo S.A.
Start price
Target price
Perf. (%)
€0.64
11.10.20
11.10.20
€0.80
04.11.21
04.11.21
-23.46%
05.11.21
05.11.21
Could be worthwhile Investment >10% per year
Nanobiotix
Start price
Target price
Perf. (%)
€8.08
29.05.20
29.05.20
€11.00
04.11.21
04.11.21
9.22%
05.11.21
05.11.21
Could be worthwhile Investment >10% per year
Transgene S.A.
Start price
Target price
Perf. (%)
€1.90
04.05.20
04.05.20
€2.80
04.11.21
04.11.21
21.05%
05.11.21
05.11.21
Could be worthwhile Investment >10% per year
Avadel Pharmaceuticals plc ADR
Start price
Target price
Perf. (%)
€7.05
03.04.20
03.04.20
€12.00
04.11.21
04.11.21
23.40%
05.11.21
05.11.21
Erytech Pharma S.A.
Start price
Target price
Perf. (%)
€3.12
17.03.20
17.03.20
€9.00
04.11.21
04.11.21
-28.37%
05.11.21
05.11.21
Could be worthwhile Investment >10% per year
AB Science S.A.
Start price
Target price
Perf. (%)
€5.24
15.11.19
15.11.19
€12.00
04.11.21
04.11.21
148.86%
05.11.21
05.11.21
Could be worthwhile Investment >10% per year
Abivax S.A.
Start price
Target price
Perf. (%)
€9.85
07.11.19
07.11.19
€28.00
04.11.21
04.11.21
184.77%
05.11.21
05.11.21
Could be very worthwhile Investment >20% year
Valneva SE
Start price
Target price
Perf. (%)
€15.83
18.10.21
18.10.21
-
18.10.22
18.10.22
23.75%
31.10.21
31.10.21
Could be very worthwhile Investment >20% year
Virbac S.A.
Start price
Target price
Perf. (%)
€275.00
28.04.21
28.04.21
€270.00
28.04.22
28.04.22
43.82%
25.10.21
25.10.21
Could be worthwhile Investment >10% per year
Valneva SE
Start price
Target price
Perf. (%)
€12.95
03.10.21
03.10.21
€20.00
03.10.22
03.10.22
15.83%
16.10.21
16.10.21
Fair valuation
Very Future proof/growth oriented business model
Could be very worthwhile Investment >20% year
Higher risks for its business
Poxel S.A.
Start price
Target price
Perf. (%)
€6.46
06.09.21
06.09.21
€5.00
06.09.22
06.09.22
-9.30%
07.10.21
07.10.21
Could be worthwhile Investment >10% per year
Innate Pharma
Start price
Target price
Perf. (%)
€6.61
18.09.21
18.09.21
€3.00
18.09.22
18.09.22
-22.01%
02.10.21
02.10.21
Probably not worthwhile Investment
Revenue decline/stagnation expected
EBIT decline/stagnation expected
Lower EBIT Margin than peer group
Nicox S.A.
Start price
Target price
Perf. (%)
€3.88
05.03.20
05.03.20
€6.00
04.11.21
04.11.21
-17.91%
29.09.21
29.09.21
Could be worthwhile Investment >10% per year